As of 2025-06-21, the Intrinsic Value of Resmed Inc (RMD) is 252.23 USD. This Resmed valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 253.68 USD, the upside of Resmed Inc is -0.60%.
The range of the Intrinsic Value is 168.53 - 536.15 USD
Based on its market price of 253.68 USD and our intrinsic valuation, Resmed Inc (RMD) is overvalued by 0.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 168.53 - 536.15 | 252.23 | -0.6% |
| DCF (Growth 10y) | 209.63 - 631.88 | 306.52 | 20.8% |
| DCF (EBITDA 5y) | 215.08 - 350.85 | 278.91 | 9.9% |
| DCF (EBITDA 10y) | 248.35 - 419.96 | 325.33 | 28.2% |
| Fair Value | 220.59 - 220.59 | 220.59 | -13.05% |
| P/E | 265.82 - 412.34 | 336.39 | 32.6% |
| EV/EBITDA | 182.85 - 296.96 | 247.88 | -2.3% |
| EPV | 75.75 - 104.41 | 90.08 | -64.5% |
| DDM - Stable | 92.62 - 397.21 | 244.91 | -3.5% |
| DDM - Multi | 138.65 - 454.69 | 211.60 | -16.6% |
| Market Cap (mil) | 37,197.10 |
| Beta | 0.71 |
| Outstanding shares (mil) | 146.63 |
| Enterprise Value (mil) | 36,937.42 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.40% |
| Cost of Debt | 4.25% |
| WACC | 8.31% |